(CercleFinance.com) – Ionis Pharmaceuticals announced on Friday that AstraZeneca had decided not to pursue the development of the PCSK9 program in hypercholesterolemia following phase 2b results deemed mixed.
In a statement, Ionis says the study showed a ‘significant’ reduction in LDL-C cholesterol after 28 weeks compared to placebo, meeting its primary endpoint.
The Californian biotech notes, however, that the trial did not meet certain predefined efficacy criteria, which led AstraZeneca to abandon the launch of a phase 3 clinical study.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
